Recent blog posts
CDH4 Biologics Sequence Review Report 2026: Cadherin-4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDH4 Biologics Sequence Review Report 2026: Cadherin-4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDH4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDON Biologics Sequence Review Report 2026: Cell adhesion molecule-related/down-regulated by oncogenes Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDON Biologics Sequence Review Report 2026: Cell adhesion molecule-related/down-regulated by oncogenes Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDON protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDHR2 Biologics Sequence Review Report 2026: Cadherin-related family member 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDHR2 Biologics Sequence Review Report 2026: Cadherin-related family member 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDHR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD163L1 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M160 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD163L1 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M160 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD163L1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH2 Biologics Sequence Review Report 2026: Cadherin-2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDH2 Biologics Sequence Review Report 2026: Cadherin-2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CDH2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD163 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M130 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD163 Biologics Sequence Review Report 2026: Scavenger receptor cysteine-rich type 1 protein M130 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD163 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD109 Biologics Sequence Review Report 2026: CD109 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD109 Biologics Sequence Review Report 2026: CD109 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD109 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRIF1 Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor-interacting factor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LRIF1 Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor-interacting factor 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LRIF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OGFR Biologics Sequence Review Report 2026: Opioid growth factor receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OGFR Biologics Sequence Review Report 2026: Opioid growth factor receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of OGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PIGR Biologics Sequence Review Report 2026: Polymeric immunoglobulin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PIGR Biologics Sequence Review Report 2026: Polymeric immunoglobulin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of PIGR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD101 Biologics Sequence Review Report 2026: Immunoglobulin superfamily member 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD101 Biologics Sequence Review Report 2026: Immunoglobulin superfamily member 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of CD101 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LCORL Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor corepressor-like protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LCORL Biologics Sequence Review Report 2026: Ligand-dependent nuclear receptor corepressor-like protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of LCORL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →